Astrocyte-derived metallothionein protects dopaminergic neurons from dopamine quinone toxicity

Ikuko Miyazaki, Masato Asanuma, Yuri Kikkawa, Mika Takeshima, Shinki Murakami, Ko Miyoshi, Norio Sogawa, Taizo Kita

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

Our previous studies demonstrated the involvement of quinone formation in dopaminergic neuron dysfunction in the L-DOPA-treated parkinsonian model and in methamphetamine (METH) neurotoxicity. We further reported that the cysteine-rich metal-binding metallothionein (MT) family of proteins protects dopaminergic neurons against dopamine (DA) quinone neurotoxicity by its quinone-quenching property. The aim of this study was to examine MT induction in astrocytes in response to excess DA and the potential neuroprotective effects of astrocyte-derived MTs against DA quinone toxicity. DA exposure significantly upregulated MT-1/-2 in cultured striatal astrocytes, but not in mesencephalic neurons. This DA-induced MT upregulation in astrocytes was blocked by treatment with a DA-transporter (DAT) inhibitor, but not by DA-receptor antagonists. Expression of nuclear factor erythroid 2-related factor (Nrf2) and its binding activity to antioxidant response element of MT-1 gene were significantly increased in the astrocytes after DA exposure. Nuclear translocation of Nrf2 was suppressed by the DAT inhibitor. Quinone formation and reduction of mesencephalic DA neurons after DA exposure were ameliorated by preincubation with conditioned media from DA-treated astrocytes. These protective effects were abrogated by MT-1/-2-specific antibody. Adding exogenous MT-1 to glial conditioned media also showed similar neuroprotective effects. Furthermore, MT-1/-2 expression was markedly elevated specifically in reactive astrocytes in the striatum of L-DOPA-treated hemi-parkinsonian mice or METH-injected mice. These results suggested that excess DA taken up by astrocytes via DAT upregulates MT-1/-2 expression specifically in astrocytes, and that MTs or related molecules secreted specifically by astrocytes protect dopaminergic neurons from damage through quinone quenching and/or scavenging of free radicals.

Original languageEnglish
Pages (from-to)435-451
Number of pages17
JournalGLIA
Volume59
Issue number3
DOIs
Publication statusPublished - Mar 2011

Fingerprint

Metallothionein
Dopaminergic Neurons
Astrocytes
Dopamine
Methamphetamine
Neuroprotective Agents
Conditioned Culture Medium
Up-Regulation
Antioxidant Response Elements
dopamine quinone
Corpus Striatum
Dopamine Plasma Membrane Transport Proteins
Dopamine Antagonists
Neuroglia
Free Radicals
Cysteine
Metals
Neurons
benzoquinone
Antibodies

Keywords

  • Dopamine transporter
  • Methamphetamine
  • Neuroprotection
  • Nrf2
  • Parkinson's disease

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience
  • Neurology

Cite this

Astrocyte-derived metallothionein protects dopaminergic neurons from dopamine quinone toxicity. / Miyazaki, Ikuko; Asanuma, Masato; Kikkawa, Yuri; Takeshima, Mika; Murakami, Shinki; Miyoshi, Ko; Sogawa, Norio; Kita, Taizo.

In: GLIA, Vol. 59, No. 3, 03.2011, p. 435-451.

Research output: Contribution to journalArticle

Miyazaki, I, Asanuma, M, Kikkawa, Y, Takeshima, M, Murakami, S, Miyoshi, K, Sogawa, N & Kita, T 2011, 'Astrocyte-derived metallothionein protects dopaminergic neurons from dopamine quinone toxicity', GLIA, vol. 59, no. 3, pp. 435-451. https://doi.org/10.1002/glia.21112
Miyazaki, Ikuko ; Asanuma, Masato ; Kikkawa, Yuri ; Takeshima, Mika ; Murakami, Shinki ; Miyoshi, Ko ; Sogawa, Norio ; Kita, Taizo. / Astrocyte-derived metallothionein protects dopaminergic neurons from dopamine quinone toxicity. In: GLIA. 2011 ; Vol. 59, No. 3. pp. 435-451.
@article{77a2f2e764de4fadb042ed4083fe7945,
title = "Astrocyte-derived metallothionein protects dopaminergic neurons from dopamine quinone toxicity",
abstract = "Our previous studies demonstrated the involvement of quinone formation in dopaminergic neuron dysfunction in the L-DOPA-treated parkinsonian model and in methamphetamine (METH) neurotoxicity. We further reported that the cysteine-rich metal-binding metallothionein (MT) family of proteins protects dopaminergic neurons against dopamine (DA) quinone neurotoxicity by its quinone-quenching property. The aim of this study was to examine MT induction in astrocytes in response to excess DA and the potential neuroprotective effects of astrocyte-derived MTs against DA quinone toxicity. DA exposure significantly upregulated MT-1/-2 in cultured striatal astrocytes, but not in mesencephalic neurons. This DA-induced MT upregulation in astrocytes was blocked by treatment with a DA-transporter (DAT) inhibitor, but not by DA-receptor antagonists. Expression of nuclear factor erythroid 2-related factor (Nrf2) and its binding activity to antioxidant response element of MT-1 gene were significantly increased in the astrocytes after DA exposure. Nuclear translocation of Nrf2 was suppressed by the DAT inhibitor. Quinone formation and reduction of mesencephalic DA neurons after DA exposure were ameliorated by preincubation with conditioned media from DA-treated astrocytes. These protective effects were abrogated by MT-1/-2-specific antibody. Adding exogenous MT-1 to glial conditioned media also showed similar neuroprotective effects. Furthermore, MT-1/-2 expression was markedly elevated specifically in reactive astrocytes in the striatum of L-DOPA-treated hemi-parkinsonian mice or METH-injected mice. These results suggested that excess DA taken up by astrocytes via DAT upregulates MT-1/-2 expression specifically in astrocytes, and that MTs or related molecules secreted specifically by astrocytes protect dopaminergic neurons from damage through quinone quenching and/or scavenging of free radicals.",
keywords = "Dopamine transporter, Methamphetamine, Neuroprotection, Nrf2, Parkinson's disease",
author = "Ikuko Miyazaki and Masato Asanuma and Yuri Kikkawa and Mika Takeshima and Shinki Murakami and Ko Miyoshi and Norio Sogawa and Taizo Kita",
year = "2011",
month = "3",
doi = "10.1002/glia.21112",
language = "English",
volume = "59",
pages = "435--451",
journal = "GLIA",
issn = "0894-1491",
publisher = "John Wiley and Sons Inc.",
number = "3",

}

TY - JOUR

T1 - Astrocyte-derived metallothionein protects dopaminergic neurons from dopamine quinone toxicity

AU - Miyazaki, Ikuko

AU - Asanuma, Masato

AU - Kikkawa, Yuri

AU - Takeshima, Mika

AU - Murakami, Shinki

AU - Miyoshi, Ko

AU - Sogawa, Norio

AU - Kita, Taizo

PY - 2011/3

Y1 - 2011/3

N2 - Our previous studies demonstrated the involvement of quinone formation in dopaminergic neuron dysfunction in the L-DOPA-treated parkinsonian model and in methamphetamine (METH) neurotoxicity. We further reported that the cysteine-rich metal-binding metallothionein (MT) family of proteins protects dopaminergic neurons against dopamine (DA) quinone neurotoxicity by its quinone-quenching property. The aim of this study was to examine MT induction in astrocytes in response to excess DA and the potential neuroprotective effects of astrocyte-derived MTs against DA quinone toxicity. DA exposure significantly upregulated MT-1/-2 in cultured striatal astrocytes, but not in mesencephalic neurons. This DA-induced MT upregulation in astrocytes was blocked by treatment with a DA-transporter (DAT) inhibitor, but not by DA-receptor antagonists. Expression of nuclear factor erythroid 2-related factor (Nrf2) and its binding activity to antioxidant response element of MT-1 gene were significantly increased in the astrocytes after DA exposure. Nuclear translocation of Nrf2 was suppressed by the DAT inhibitor. Quinone formation and reduction of mesencephalic DA neurons after DA exposure were ameliorated by preincubation with conditioned media from DA-treated astrocytes. These protective effects were abrogated by MT-1/-2-specific antibody. Adding exogenous MT-1 to glial conditioned media also showed similar neuroprotective effects. Furthermore, MT-1/-2 expression was markedly elevated specifically in reactive astrocytes in the striatum of L-DOPA-treated hemi-parkinsonian mice or METH-injected mice. These results suggested that excess DA taken up by astrocytes via DAT upregulates MT-1/-2 expression specifically in astrocytes, and that MTs or related molecules secreted specifically by astrocytes protect dopaminergic neurons from damage through quinone quenching and/or scavenging of free radicals.

AB - Our previous studies demonstrated the involvement of quinone formation in dopaminergic neuron dysfunction in the L-DOPA-treated parkinsonian model and in methamphetamine (METH) neurotoxicity. We further reported that the cysteine-rich metal-binding metallothionein (MT) family of proteins protects dopaminergic neurons against dopamine (DA) quinone neurotoxicity by its quinone-quenching property. The aim of this study was to examine MT induction in astrocytes in response to excess DA and the potential neuroprotective effects of astrocyte-derived MTs against DA quinone toxicity. DA exposure significantly upregulated MT-1/-2 in cultured striatal astrocytes, but not in mesencephalic neurons. This DA-induced MT upregulation in astrocytes was blocked by treatment with a DA-transporter (DAT) inhibitor, but not by DA-receptor antagonists. Expression of nuclear factor erythroid 2-related factor (Nrf2) and its binding activity to antioxidant response element of MT-1 gene were significantly increased in the astrocytes after DA exposure. Nuclear translocation of Nrf2 was suppressed by the DAT inhibitor. Quinone formation and reduction of mesencephalic DA neurons after DA exposure were ameliorated by preincubation with conditioned media from DA-treated astrocytes. These protective effects were abrogated by MT-1/-2-specific antibody. Adding exogenous MT-1 to glial conditioned media also showed similar neuroprotective effects. Furthermore, MT-1/-2 expression was markedly elevated specifically in reactive astrocytes in the striatum of L-DOPA-treated hemi-parkinsonian mice or METH-injected mice. These results suggested that excess DA taken up by astrocytes via DAT upregulates MT-1/-2 expression specifically in astrocytes, and that MTs or related molecules secreted specifically by astrocytes protect dopaminergic neurons from damage through quinone quenching and/or scavenging of free radicals.

KW - Dopamine transporter

KW - Methamphetamine

KW - Neuroprotection

KW - Nrf2

KW - Parkinson's disease

UR - http://www.scopus.com/inward/record.url?scp=78751691004&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78751691004&partnerID=8YFLogxK

U2 - 10.1002/glia.21112

DO - 10.1002/glia.21112

M3 - Article

C2 - 21264950

AN - SCOPUS:78751691004

VL - 59

SP - 435

EP - 451

JO - GLIA

JF - GLIA

SN - 0894-1491

IS - 3

ER -